The Cryopyrin-Associated Periodic Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Cryopyrin-Associated Periodic Syndrome Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cryopyrin-Associated Periodic Syndrome Market.
Some of the key takeaways from the Cryopyrin-Associated Periodic Syndrome Pipeline Report:
-
Companies across the globe are diligently working toward developing novel Cryopyrin-Associated Periodic Syndrome treatment therapies with a considerable amount of success over the years.
-
Cryopyrin-Associated Periodic Syndrome companies working in the treatment market are NLRP3 Secarna Pharmaceuticals, Novartis Pharmaceutical, Zydus Lifesciences Ltd., Novartis Pharmaceuticals, Aclaris Therapeutics, Inflazome, and others, are developing therapies for the Cryopyrin-Associated Periodic Syndrome treatment
-
Emerging Cryopyrin-Associated Periodic Syndrome therapies in the different phases of clinical trials are- Research Program, DFV890, ZYIL1, DFV890, Zunsemetinib, IZD334, and others are expected to have a significant impact on the Cryopyrin-Associated Periodic Syndrome market in the coming years.
-
In March 2024, Ventyx Biosciences has completed a Phase 2 trial of VTX2735 in patients with cryopyrin-associated periodic syndromes (CAPS), a group of rare autoinflammatory diseases caused by gain-of-function mutations in the NLRP3 gene. The trial enrolled 7 patients with familial cold autoinflammatory syndrome (FCAS), the most common form of CAPS. Treatment with VTX2735 showed significant improvements in disease activity, including an 85% average reduction in the Key Symptom Score during Treatment Period 1.
Cryopyrin-Associated Periodic Syndrome Overview
Cryopyrin-Associated Periodic Syndromes (CAPS) are a group of rare, inherited autoinflammatory disorders caused by mutations in the NLRP3 gene, which encodes the cryopyrin protein. This protein plays a key role in regulating inflammation in the body. CAPS includes conditions such as Familial Cold Autoinflammatory Syndrome (FCAS), Muckle-Wells Syndrome (MWS), and Neonatal-onset Multisystem Inflammatory Disease (NOMID). These conditions are characterized by recurrent episodes of fever, rash, joint pain, and inflammation, often triggered by environmental factors like cold temperatures. CAPS can lead to long-term damage if untreated. Treatment typically involves medications to control inflammation, such as interleukin-1 (IL-1) inhibitors.
Get a Free Sample PDF Report to know more about Cryopyrin-Associated Periodic Syndrome Pipeline Therapeutic Assessment-
Emerging Cryopyrin-Associated Periodic Syndrome Drugs Under Different Phases of Clinical Development Include:
-
Research Program: NLRP3 Secarna Pharmaceuticals
-
DFV890: Novartis Pharmaceutical
-
ZYIL1: Zydus Lifesciences Ltd.
-
DFV890: Novartis Pharmaceuticals
-
Zunsemetinib : Aclaris Therapeutics
-
IZD334: Inflazome
Cryopyrin-Associated Periodic Syndrome Route of Administration
Cryopyrin-Associated Periodic Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
-
Intra-articular
-
Intraocular
-
Intrathecal
-
Intravenous
-
Ophthalmic
-
Oral
-
Parenteral
-
Subcutaneous
-
Topical
-
Transdermal
Cryopyrin-Associated Periodic Syndrome Molecule Type
Cryopyrin-Associated Periodic Syndrome Products have been categorized under various Molecule types, such as
-
Oligonucleotide
-
Peptide
-
Small molecule
Cryopyrin-Associated Periodic Syndrome Pipeline Therapeutics Assessment
-
Cryopyrin-Associated Periodic Syndrome Assessment by Product Type
-
Cryopyrin-Associated Periodic Syndrome By Stage and Product Type
-
Cryopyrin-Associated Periodic Syndrome Assessment by Route of Administration
-
Cryopyrin-Associated Periodic Syndrome By Stage and Route of Administration
-
Cryopyrin-Associated Periodic Syndrome Assessment by Molecule Type
-
Cryopyrin-Associated Periodic Syndrome by Stage and Molecule Type
DelveInsight’s Cryopyrin-Associated Periodic Syndrome Report covers around 4+ products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
-
Route of Administration
Further Cryopyrin-Associated Periodic Syndrome product details are provided in the report. Download the Cryopyrin-Associated Periodic Syndrome pipeline report to learn more about the emerging Cryopyrin-Associated Periodic Syndrome therapies
Some of the key companies in the Cryopyrin-Associated Periodic Syndrome Therapeutics Market include:
Key companies developing therapies for Cryopyrin-Associated Periodic Syndrome are – Zydus Cadila, Novartis, Inflazome, Roche, Aclaris Therapeutics, Mabpharm, Regeneron Pharmaceuticals, and others.
Cryopyrin-Associated Periodic Syndrome Pipeline Analysis:
The Cryopyrin-Associated Periodic Syndrome pipeline report provides insights into
-
The report provides detailed insights about companies that are developing therapies for the treatment of Cryopyrin-Associated Periodic Syndrome with aggregate therapies developed by each company for the same.
-
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cryopyrin-Associated Periodic Syndrome Treatment.
-
Cryopyrin-Associated Periodic Syndrome key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
Cryopyrin-Associated Periodic Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cryopyrin-Associated Periodic Syndrome market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Cryopyrin-Associated Periodic Syndrome drugs and therapies
Cryopyrin-Associated Periodic Syndrome Pipeline Market Drivers
-
Increase in prevalence of Cryopyrin Associated Periodic Syndrome, increase in Research and Development are some of the important factors that are fueling the Cryopyrin-Associated Periodic Syndrome Market.
Cryopyrin-Associated Periodic Syndrome Pipeline Market Barriers
-
However, high cost associated with the treatment, lack of effective treatment available and other factors are creating obstacles in the Cryopyrin-Associated Periodic Syndrome Market growth.
Scope of Cryopyrin-Associated Periodic Syndrome Pipeline Drug Insight
-
Coverage: Global
-
Key Cryopyrin-Associated Periodic Syndrome Companies: NLRP3 Secarna Pharmaceuticals, Novartis Pharmaceutical, Zydus Lifesciences Ltd., Novartis Pharmaceuticals, Aclaris Therapeutics, Inflazome, and others
-
Key Cryopyrin-Associated Periodic Syndrome Therapies: Research Program, DFV890, ZYIL1, DFV890, Zunsemetinib, IZD334, and others
-
Cryopyrin-Associated Periodic Syndrome Therapeutic Assessment: Cryopyrin-Associated Periodic Syndrome current marketed and Cryopyrin-Associated Periodic Syndrome emerging therapies
-
Cryopyrin-Associated Periodic Syndrome Market Dynamics: Cryopyrin-Associated Periodic Syndrome market drivers and Cryopyrin-Associated Periodic Syndrome market barriers
Request for Sample PDF Report for Cryopyrin-Associated Periodic Syndrome Pipeline Assessment and clinical trials
Table of Contents
1. Cryopyrin-Associated Periodic Syndrome Report Introduction
2. Cryopyrin-Associated Periodic Syndrome Executive Summary
3. Cryopyrin-Associated Periodic Syndrome Overview
4. Cryopyrin-Associated Periodic Syndrome- Analytical Perspective In-depth Commercial Assessment
5. Cryopyrin-Associated Periodic Syndrome Pipeline Therapeutics
6. Cryopyrin-Associated Periodic Syndrome Late Stage Products (Phase II/III)
7. Cryopyrin-Associated Periodic Syndrome Mid Stage Products (Phase II)
8. Cryopyrin-Associated Periodic Syndrome Early Stage Products (Phase I)
9. Cryopyrin-Associated Periodic Syndrome Preclinical Stage Products
10. Cryopyrin-Associated Periodic Syndrome Therapeutics Assessment
11. Cryopyrin-Associated Periodic Syndrome Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Cryopyrin-Associated Periodic Syndrome Key Companies
14. Cryopyrin-Associated Periodic Syndrome Key Products
15. Cryopyrin-Associated Periodic Syndrome Unmet Needs
16 . Cryopyrin-Associated Periodic Syndrome Market Drivers and Barriers
17. Cryopyrin-Associated Periodic Syndrome Future Perspectives and Conclusion
18. Cryopyrin-Associated Periodic Syndrome Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/